Biomx Ltd., an Israeli microbiome company developing customized phage therapies, has closed a $32 million series B equity financing it said will be used primarily to advance its acne and inflammatory bowel disease (IBD) candidates to the clinic. BX-001, the acne program for which it has secured a global cosmetics-focused partner, is expected to enter a phase I trial in the second half of this year with an expected readout by year-end ahead of an additional trial in 2020. It will be followed by trials for the company's IBD program, BX-002, toward the end of 2020, Biomx CEO Jonathan Solomon told BioWorld.